Abstract
NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline), a selective antagonist of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptors, at an anticonvulsant dose of 40 mg/kg (i.p.), was shown in vivo to have no effects on either the field potentials in the piriform cortex or those in the dentate gyrus of the hippocampus. The same dose of NBQX also exerted no significant effects on long-term potentiation in the hippocampus. These results suggest that the mechanism underlying the anticonvulsant action of NBQX in vivo does not involve a suppressive action on physiological synaptic transmission. The possible clinical usefulness of AMPA receptor antagonists as antiepiletic drugs is suggested.
| Original language | English |
|---|---|
| Pages (from-to) | 279-282 |
| Number of pages | 4 |
| Journal | Brain Research |
| Volume | 683 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Jun 19 1995 |
Keywords
- Field potential
- In vivo
- Long-term potentiation
- NBQX
- Selective AMPA receptor antagonist
ASJC Scopus subject areas
- Neuroscience(all)
- Molecular Biology
- Clinical Neurology
- Developmental Biology
Fingerprint Dive into the research topics of 'NBQX, a selective antagonist of the AMPA receptor, affects neither field potentials nor long-term potentiation in vivo'. Together they form a unique fingerprint.
Cite this
Sato, K., Morimoto, K., Yamada, N., Kuroda, S., & Hayabara, T. (1995). NBQX, a selective antagonist of the AMPA receptor, affects neither field potentials nor long-term potentiation in vivo. Brain Research, 683(2), 279-282. https://doi.org/10.1016/0006-8993(95)00266-S